🇺🇸·15h agoIndustry
Safety and Efficacy of an Off-the-Shelf Anti-CD19 CAR T-Cell Therapy With Reduced Conditioning in SLE: A Phase 1 Study Supporting Same-Day Discharge
Publisher
F
Fate Therapeutics
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on fatetherapeutics.com
Leave the platform to read the original full article on the publisher site.
Source: Fate Therapeutics
Scope: Industry
Related coverage
More related coverage
Amarin Corporation·6h ago
AME และ AME Group ได้รับตราสัญลักษณ์มาตรฐานไมซ์ในงาน MICE Standards Day 2026
WuXi Biologics·8h ago
Bispecific and multi-specific antibody development journey at WuXi Biologics
GH Research·14h ago
GH Research Announces Publication of Phase 2a Postpartum Depression Results
Fate Therapeutics·15h ago